RxDoctor Payments Data

Robert Lowsky, MD

Hematology · Stanford, CANPI 1083756308

Payments from drug & device makers

$311,724in general payments, 2019–2025

Across 29 payments — averaging $10,749 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • CSL Behring$307K
  • Amgen$5K

What the payments were for

  • Consulting fees$4,675100%

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
CSL Behring28$307,049
Amgen1$4,675

How this compares

$311,724 in reported general payments places this provider in the 60th percentile of 178 hematology providers in California.

See all hematology providers in California

Medicare billing

Part B allowed, 2024
$42,047
Medicare patients
82
Services billed
271

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JakafiRuxolitinib Phosphate59$943,016
RezurockBelumosudil Mesylate40$720,730
HizentraImmun Glob G(Igg)/Pro/Iga 0-5011$23,579
Voriconazole13$9,556
Atovaquone13$2,400
Acyclovir63$1,688
Dexamethasone15$645
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim39$459
Mycophenolate Mofetil13$422
Prednisone31$284
Entecavir11$172
Famotidine11$151
Pantoprazole Sodium19$112

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
CSL BehringHizentra$307,049$23,57911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 178 hematology providers in California.

Other hematology in Stanford

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →